research Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib
Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
Search
forLearn
0 / 0 results — no results
Research
5 / 7 results
research Evaluation of Serum Ferritin, Creatinine, and Liver Enzymes in Patients with Beta-Thalassemia After Administration of Deferasirox
The study on 85 patients with ß-thalassemia in Kirkuk, Iraq, found that deferasirox, an oral iron chelator, effectively reduced serum ferritin levels in 55.3% of patients, indicating a decrease in iron overload. Some adverse effects were observed, including elevated serum creatinine in 25.8% of patients, elevated liver enzymes, and hair loss in 2 patients. Despite these side effects, deferasirox was generally well-tolerated, and its adverse effects could be managed by adjusting the dosage. The study concludes that deferasirox is a suitable treatment for managing iron overload in ß-thalassemia patients.
research Section 2: Single Best Answer Questions 51–120
The document tests knowledge and decision-making in hematology through multiple-choice questions.
research Single Best Answers for Hematology Specialist Trainees
The document provides 70 multiple choice questions to improve haematology skills.
research Advancements and Applications of Injectable Hydrogel Composites in Biomedical Research and Therapy
Injectable hydrogels are becoming increasingly useful in medicine for drug delivery and tissue repair.
Community Join
0 / 0 results — no results